CN118695864A - 用于治疗化脓性汗腺炎的特定n-(1-氰基-2-苯乙基)-1,4-氧杂氮杂环庚烷-2-甲酰胺 - Google Patents
用于治疗化脓性汗腺炎的特定n-(1-氰基-2-苯乙基)-1,4-氧杂氮杂环庚烷-2-甲酰胺 Download PDFInfo
- Publication number
- CN118695864A CN118695864A CN202380021843.7A CN202380021843A CN118695864A CN 118695864 A CN118695864 A CN 118695864A CN 202380021843 A CN202380021843 A CN 202380021843A CN 118695864 A CN118695864 A CN 118695864A
- Authority
- CN
- China
- Prior art keywords
- subject
- administration period
- months
- biological sample
- carboxamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263310751P | 2022-02-16 | 2022-02-16 | |
| US63/310,751 | 2022-02-16 | ||
| PCT/US2023/062731 WO2023159120A1 (en) | 2022-02-16 | 2023-02-16 | Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118695864A true CN118695864A (zh) | 2024-09-24 |
Family
ID=87579133
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202380021843.7A Pending CN118695864A (zh) | 2022-02-16 | 2023-02-16 | 用于治疗化脓性汗腺炎的特定n-(1-氰基-2-苯乙基)-1,4-氧杂氮杂环庚烷-2-甲酰胺 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250144116A1 (https=) |
| EP (1) | EP4479059A4 (https=) |
| JP (1) | JP2025508359A (https=) |
| KR (1) | KR20240148350A (https=) |
| CN (1) | CN118695864A (https=) |
| AU (1) | AU2023221393A1 (https=) |
| CA (1) | CA3244131A1 (https=) |
| GB (1) | GB2630719A (https=) |
| IL (1) | IL314769A (https=) |
| MX (1) | MX2024009995A (https=) |
| WO (1) | WO2023159120A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2699580T3 (https=) | 2014-01-24 | 2018-02-24 | ||
| HUE070049T2 (hu) | 2018-03-01 | 2025-05-28 | Astrazeneca Ab | (2S)-{(1S)-1-ciano-2-[4-(3-metil-2-oxo-2,3-dihidro-1,3-benzoxazol-5-il)fenil]etil} -1,4-oxazepán-2-karboxamidot tartalmazó gyógyászati készítmények |
| WO2020018547A1 (en) | 2018-07-17 | 2020-01-23 | Insmed Incorporated | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2699580T3 (https=) * | 2014-01-24 | 2018-02-24 | ||
| KR20240091302A (ko) * | 2016-07-29 | 2024-06-21 | 인스메드 인코포레이티드 | 기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드 |
| CA3089240A1 (en) * | 2018-02-07 | 2019-08-15 | Insmed Incorporated | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating anca associated vasculitides |
| MX2021012548A (es) * | 2019-04-17 | 2023-01-05 | Azora Therapeutics Inc | Composiciones topicas y metodos para el tratamiento de enfermedades inflamatorias de la piel. |
| WO2024026433A2 (en) * | 2022-07-28 | 2024-02-01 | Insmed Incorporated | Novel dpp1 inhibitors and uses thereof |
-
2023
- 2023-02-16 EP EP23757082.5A patent/EP4479059A4/en active Pending
- 2023-02-16 CN CN202380021843.7A patent/CN118695864A/zh active Pending
- 2023-02-16 GB GB2412566.8A patent/GB2630719A/en active Pending
- 2023-02-16 WO PCT/US2023/062731 patent/WO2023159120A1/en not_active Ceased
- 2023-02-16 IL IL314769A patent/IL314769A/en unknown
- 2023-02-16 US US18/838,823 patent/US20250144116A1/en active Pending
- 2023-02-16 MX MX2024009995A patent/MX2024009995A/es unknown
- 2023-02-16 KR KR1020247027154A patent/KR20240148350A/ko active Pending
- 2023-02-16 JP JP2024546431A patent/JP2025508359A/ja active Pending
- 2023-02-16 CA CA3244131A patent/CA3244131A1/en active Pending
- 2023-02-16 AU AU2023221393A patent/AU2023221393A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250144116A1 (en) | 2025-05-08 |
| WO2023159120A1 (en) | 2023-08-24 |
| IL314769A (en) | 2024-10-01 |
| KR20240148350A (ko) | 2024-10-11 |
| MX2024009995A (es) | 2024-08-22 |
| CA3244131A1 (en) | 2023-08-24 |
| EP4479059A4 (en) | 2026-01-28 |
| AU2023221393A1 (en) | 2024-08-15 |
| EP4479059A1 (en) | 2024-12-25 |
| JP2025508359A (ja) | 2025-03-26 |
| GB2630719A (en) | 2024-12-04 |
| GB202412566D0 (en) | 2024-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN118695864A (zh) | 用于治疗化脓性汗腺炎的特定n-(1-氰基-2-苯乙基)-1,4-氧杂氮杂环庚烷-2-甲酰胺 | |
| JP5749255B2 (ja) | Ｌ−オルニチンフェニル酢酸塩を用いる門脈圧亢進の治療及び肝機能の修復 | |
| US20250049813A1 (en) | Certain n-(1-cyan0-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating chronic rhinosinusitis | |
| CN106999593A (zh) | 用于纤维化治疗的赛尼克韦罗组合疗法 | |
| US10806735B2 (en) | Use of neutrophil elastase inhibitors in liver disease | |
| US20250268876A1 (en) | Treatment of hidradenitis suppurativa with orismilast | |
| US20230338367A1 (en) | Treatment of prurigo nodularis | |
| JP2024133735A (ja) | Ｉｖ型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物 | |
| JP2016503803A (ja) | 酢酸グラチラマーの経粘膜送達 | |
| JP2026069500A (ja) | 線維症を治療するためのシクロスポリン類似体の使用 | |
| US20260069578A1 (en) | Treatment of neutrophilic dermatoses | |
| WO2020014342A1 (en) | Treatment of the pruritic symptoms of liver disease | |
| BRPI0713647A2 (pt) | formulações farmacêuticas e composições de um antagonista seletivo cxcr2 ou cxcr1 e métodos para o uso do mesmo visando o tratamento de distúrbios inflamatórios | |
| TW202216129A (zh) | 排尿症狀治療劑 | |
| JP2022515615A (ja) | 慢性炎症性腸疾患の治療のためのｐａｒ－１アンタゴニストの使用 | |
| US20240122956A1 (en) | Application of Naringin Combined with Rapamycin in Preparation of Medications for Treating Hyperlipidemia | |
| JPWO2005063253A1 (ja) | アレルギー症状治療用医薬組成物 | |
| WO2025078838A1 (en) | Alvelestat and alpha- 1 antitrypsin for treating respiratory disorders | |
| TWI590825B (zh) | 治療癌症的基於硫□酮之自體吞噬抑制劑治療 | |
| CN118369098A (zh) | 用于治疗进行性纤维化间质性肺病的新颖治疗组合 | |
| HK40003409A (en) | Treatment of prurigo nodularis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |